TCRT - Multiplikator forward rega marang pendapatan alaunos.com

Alaunos Therapeutics (TCRT) is developing innovative TCR-T cancer therapies, leveraging clinic partnerships to support R&D and cash flows. The firm's forward P/S, where the current parameter is 583.70, highlights liquidity decline risks amid US export bans to Asia. Restructuring and the suspension of key programs have severely weakened competitive advantages, leaving only limited patent value.

Alaunos Therapeutics, Inc. - Prakiraan rega marang pendapatan TCRT (periode 04.07.2022 - 16.05.2026)

alaunos.com - rincian analitis lan metrik utama (TCRT)

- rega pasar lan target rega analis:

Bagan rega Alaunos Therapeutics, Inc.|TCRT - Bagan rega target

- statistik kapitalisasi pasar:

Biji pasar Alaunos Therapeutics, Inc.|TCRT - Nilai Dipunlarasaken Utang lan Kas

- rincian valuasi buku bisnis:

Nilai Buku saben Saham Alaunos Therapeutics|TCRT - Nilai Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku alaunos.com|TCRT - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Utang marang Ekuitas Alaunos Therapeutics|TCRT - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Alaunos Therapeutics, Inc.|TCRT - Utang kumulatif perusahaan|Utang marang nilai buku Alaunos Therapeutics, Inc.|TCRT - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Alaunos Therapeutics|Rasio cepet alaunos.com

- rincian asil keuangan lan kelipatan valuasi:

TCRT - Bathi pungkasan|Proyeksi bathi mangsa ngarep Alaunos Therapeutics|TCRT - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Alaunos Therapeutics, Inc.|TCRT - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Alaunos Therapeutics, Inc.|TCRT - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Alaunos Therapeutics|TCRT - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan alaunos.com|TCRT - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Alaunos Therapeutics

- data pendapatan lan penerimaan dodolan:

TCRT - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan Alaunos Therapeutics, Inc.|TCRT - Rasio rega marang pendapatan|Multiplikator Forward P/S Alaunos Therapeutics, Inc.

Analisis wiwitan perusahaan:Alaunos (TCRT)

The assessment of the margin of safety for Alaunos Therapeutics (TCRT) is based on the ratio of market capitalization to expected revenue, which determines the value of each unit of future sales. Analyzing the company's projected P/S chart, an investor can see the balance between growth potential and the risk of a price collapse due to a high cash burn rate and the threats of clinical trial suspensions for its cell therapy.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Legend Biotech Corporation LEGN|Sana Biotechnology Inc - Rasio rega marang prakiraan pendapatan|AUTL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ALLO (Allogene Corp)|RNAC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Cellectis CLLS|CRBU (Caribou Biosciences, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Instil Bio Inc. TIL|Rasio rega marang prakiraan pendapatan Genenta Science S.p.A. (GNTA)|centurytx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S JSPR (Jasper Therapeutics, Inc.)|Senti Bio (SNTI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ADAP: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CERO (CERo Therapeutics)|ACHL (achillestx.com) - Multiplikator forward rega marang pendapatan|CRGX: Rasio rega marang pendapatan sing dikarepake|PSTX (Poseida Therapeutics) - Multiplikator Forward P/S|TSVT: Rega forward marang dodolan|Multiplikator Forward P/S GRCL